Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that Aurgalys, an equity research firm dedicated to life sciences, initiated the coverage of the company.
Their first financial analysis note, entitled «Quantum Genomics could revolutionize the hypertension market», is available on the website of Quantum Genomics (wwww.quantum-genomics.com), Investors section, and on Aurgalys website (www.aurgalys.com).
Click here to consult Aurgalys's equity research
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
Contacts
| Quantum Genomics Lionel Ségard CEO (+33) 1 60 13 76 80 | Quantum Genomics Marc Karako CFO - Investor relations (+33) 1 60 13 76 84 [email protected] | ACTUS Jean-Michel Marmillon Press relations (33) 1 53 67 07 80 [email protected] |
- SECURITY MASTER Key: ypluZplmlpyanWtqZp1rmZNja5dqxWKYZmSWmGdpa8ucmJxglmySb8rLZmxonWdp
- Check this key: https://www.security-master-key.com.